Virtus ETF Advisers’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Virtus ETF Advisers’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-15,039	Closed	-$141K	–	487
2022 Q1	$141K	Sell	15,039 -893	-6%	-$8.87K	0.06%	235
2021 Q4	$189K	Buy	15,932 +4,597	+41%	+$53.1K	0.07%	233
2021 Q3	$129K	Sell	11,335 -595	-5%	-$8.18K	0.06%	366
2021 Q2	$214K	Sell	11,930 -10,982	-48%	-$177K	0.09%	296
2021 Q1	$355K	Buy	22,912 +409	+2%	+$5.92K	0.15%	207
2020 Q4	$275K	Sell	22,503 -9,734	-30%	-$136K	0.11%	265
2020 Q3	$414K	Sell	32,237 -4,403	-12%	-$38K	0.22%	163
2020 Q2	$372K	Buy	+36,640	New	+$337K	0.18%	230
2018 Q4	–	Sell	-15,992	Closed	-$640K	–	398
2018 Q3	$640K	Sell	15,992 -11,506	-42%	-$327K	0.07%	88
2018 Q2	$778K	Buy	27,498 +7,401	+37%	+$164K	0.69%	45
2018 Q1	$307K	Buy	20,097 +10,646	+113%	+$253K	0.27%	115
2017 Q4	$308K	Buy	+9,451	New	+$255K	0.39%	119

Other funds holding MRNS

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Virtus ETF Advisers's MRNS Position: Q2 2022 in Review

Virtus ETF Advisers sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2022, closing a stake of 15,039 shares — an estimated $141K sold.

Virtus ETF Advisers first reported a position in MRNS in Q4 2017 and held it in 12 quarters. The position peaked at $778K in Q2 2018. 73 funds tracked by Wall St. Rank hold MRNS as of Q2 2022.

Virtus ETF Advisers reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2022 after selling out during the quarter.
Virtus ETF Advisers sold 15,039 Marinus Pharmaceuticals, Inc shares in Q2 2022, an estimated $141K.
Virtus ETF Advisers first reported a position in Marinus Pharmaceuticals, Inc in Q4 2017 and held it in 12 quarters.
Virtus ETF Advisers's Marinus Pharmaceuticals, Inc position peaked at $778K in Q2 2018.
73 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2022.

Based on Virtus ETF Advisers's 13F filing for Q2 2022, filed 12 Aug 2022.